Richard Levy - Incyte President
| INCY Stock | USD 52.72 0.50 0.94% |
President
Dr. Richard S. Levy M.D. is the Executive Vice President Chief Drug Development Officer of Incyte Corporationrationration. He joined the company as Senior Vice President of Drug Development in August 2003. Prior to joining Incyte Dr. Levy held positions of increasing responsibilities in drug development clinical research and regulatory affairs at Celgene from 2002 to 2003 DuPont Pharmaceuticals Company from 1997 to 2002 and Sandoz from 1991 to 1997. Prior to joining the pharmaceutical industry Dr. Levy was Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University and his M.D. from the University of Pennsylvania. since 2009.
| Age | 57 |
| Tenure | 15 years |
| Address | 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 |
| Phone | 302 498 6700 |
| Web | https://www.incyte.com |
Richard Levy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Levy against Incyte stock is an integral part of due diligence when investing in Incyte. Richard Levy insider activity provides valuable insight into whether Incyte is net buyers or sellers over its current business cycle. Note, Incyte insiders must abide by specific rules, including filing SEC forms every time they buy or sell Incyte'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Levy over six months ago Acquisition by Richard Levy of 40000 shares of Kodiak Sciences subject to Rule 16b-3 |
Incyte Management Efficiency
The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Peter Smith | Alnylam Pharmaceuticals | 58 | |
| Jayson Dallas | Ultragenyx | 49 | |
| Michael Yang | ACADIA Pharmaceuticals | 55 | |
| Patrick ONeil | Ionis Pharmaceuticals | 44 | |
| Ahmad Sadr | Apellis Pharmaceuticals | 44 | |
| David Allsop | Amicus Therapeutics | N/A | |
| Karah Parschauer | Ultragenyx | 40 | |
| Jing Marantz | Alnylam Pharmaceuticals | N/A | |
| Srdjan Stankovic | ACADIA Pharmaceuticals | 61 | |
| Stephen Davis | ACADIA Pharmaceuticals | 57 | |
| Kurt Andrews | Amicus Therapeutics | 47 | |
| Camille Bedrosian | Ultragenyx | 65 | |
| John Kirk | Amicus Therapeutics | 57 | |
| Willem Weperen | Amicus Therapeutics | N/A | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Enrique Dilone | Amicus Therapeutics | 47 | |
| Jeff Ajer | Biomarin Pharmaceutical | 55 | |
| Jill Weimer | Amicus Therapeutics | N/A | |
| John Pinion | Ultragenyx | 52 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0646 |
Incyte Leadership Team
Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Stein, Senior Vice President and Chief Medical Officer | ||
| Paul Trower, Principal Accounting Officer and VP of Fin. | ||
| Thomas Tray, Chief Finance | ||
| Pamela Murphy, Vice Communications | ||
| Eric Siegel, Executive Vice President General Counsel | ||
| Vijay Iyengar, Executive Vice President Global Strategy and Corporate Development` | ||
| Reid Huber, Chief Scientific Officer and Executive VP | ||
| Richard Levy, Executive Vice President Chief Drug Development and Medical Officer | ||
| Christine Chiou, Head Relations | ||
| PharmD MBA, Executive America | ||
| JeanJacques Bienaime, Independent Director | ||
| Paul Brooke, Independent Director | ||
| Maria Pasquale, Executive Vice President General Counsel | ||
| Christiana Stamoulis, CFO, Executive Vice President | ||
| Steven MD, Executive Officer | ||
| Julian Baker, Independent Vice Chairman of the Board | ||
| Sheila Denton, Executive Counsel | ||
| Michael Booth, VP - Investor Relations | ||
| David Gryska, CFO, Executive Vice President | ||
| Paul Friedman, Director | ||
| Wenqing Yao, Executive Vice President - Discovery Medicinal and Process Chemistry | ||
| Jacqualyn Fouse, Director | ||
| Paula Swain, Executive Resources | ||
| Paul Clancy, Director | ||
| Wendy Dixon, Independent Director | ||
| Michael Morrissey, Executive Operations | ||
| Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee | ||
| Barry Flannelly, Executive Vice President - Business Development and Strategic Planning | ||
| Dashyant Dhanak, Executive Vice President Chief Scientific Officer | ||
| Christiana MBA, Executive CFO | ||
| Maria JD, Gen VP | ||
| MBA MBA, Ex America |
Incyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0646 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 8.35 B | ||||
| Shares Outstanding | 224.53 M | ||||
| Shares Owned By Insiders | 1.58 % | ||||
| Shares Owned By Institutions | 98.42 % | ||||
| Number Of Shares Shorted | 8.06 M | ||||
| Price To Earning | 19.17 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.324 | Earnings Share 2.65 | Revenue Per Share 16.526 | Quarterly Revenue Growth 0.093 | Return On Assets 0.0646 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.